These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 2295807)

  • 1. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis.
    Jaffe CL; Rachamim N; Sarfstein R
    J Immunol; 1990 Jan; 144(2):699-706. PubMed ID: 2295807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
    Rachamim N; Jaffe CL
    J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin.
    Mukherjee M; Bhattacharyya A; Duttagupta S
    Med Sci Monit; 2002 Apr; 8(4):BR117-22. PubMed ID: 11951057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
    Tonui WK; Titus RG
    Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of amastigote-specific antigens of Leishmania donovani using kala-azar patient sera.
    Gupta N; Goyal N; Bhatia N; Kamboj KK; Rastogi AK
    Indian J Exp Biol; 2001 Jul; 39(7):623-8. PubMed ID: 12019753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production and characterization of species-specific monoclonal antibodies against Leishmania donovani for immunodiagnosis.
    Jaffe CL; Bennett E; Grimaldi G; McMahon-Pratt D
    J Immunol; 1984 Jul; 133(1):440-7. PubMed ID: 6373932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes.
    Ali N; Afrin F
    J Parasitol; 1997 Feb; 83(1):70-5. PubMed ID: 9057699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species and stage specificity of Leishmania donovani antigens.
    White AC; Hanham C
    J Parasitol; 1991 Feb; 77(1):142-50. PubMed ID: 1704058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leishmania: amastigotes synthesize conserved secretory acid phosphatases during human infection.
    Ellis SL; Shakarian AM; Dwyer DM
    Exp Parasitol; 1998 Jun; 89(2):161-8. PubMed ID: 9635439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
    Bhowmick S; Mazumdar T; Sinha R; Ali N
    J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
    Bhardwaj S; Vasishta RK; Arora SK
    Exp Parasitol; 2009 Jan; 121(1):29-37. PubMed ID: 18983842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis.
    Garg R; Gupta SK; Tripathi P; Hajela K; Sundar S; Naik S; Dube A
    Vaccine; 2006 Apr; 24(15):2900-9. PubMed ID: 16448729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.
    Kumari S; Samant M; Misra P; Khare P; Sisodia B; Shasany AK; Dube A
    Vaccine; 2008 Oct; 26(45):5700-11. PubMed ID: 18762224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies specific for the amastigote stage of Leishmania pifanoi. I. Characterization of antigens associated with stage- and species-specific determinants.
    Pan AA; McMahon-Pratt D
    J Immunol; 1988 Apr; 140(7):2406-14. PubMed ID: 2450920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The major concanavalin A-binding surface glycoprotein of Leishmania donovani chagasi promastigotes is involved in attachment to human macrophages.
    Wilson ME; Hardin KK
    J Immunol; 1988 Jul; 141(1):265-72. PubMed ID: 3379307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice.
    Kaur J; Kaur T; Kaur S
    Acta Trop; 2011 Jul; 119(1):50-6. PubMed ID: 21530477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies specific for Leishmania tropica. I. Characterization of antigens associated with stage- and species-specific determinants.
    Jaffe CL; McMahon-Pratt D
    J Immunol; 1983 Oct; 131(4):1987-93. PubMed ID: 6194223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.